<DOC>
	<DOCNO>NCT00528528</DOCNO>
	<brief_summary>The purpose study explore efficacy , safety , tolerability , pharmacokinetics ( study way drug enters leave blood tissue time ) , pharmacokinetic-pharmacodynamic relationship telaprevir administer two different dos combination two standard therapy commercially available chronic ( last long time ) genotype 1 Hepatitis ( inflammation liver ) C virus ( HCV ) infection .</brief_summary>
	<brief_title>An Open-Label Study Telaprevir Administered Every 12 8 Hours Combination With One Two Pegylated Interferons Ribavirin Treatment-Naive Genotype 1 Chronic Hepatitis C Participants</brief_title>
	<detailed_description>This Phase 2a , open-label ( people know identity intervention ) , multicenter trial ( conduct one center ) participants chronic genotype 1 HCV infection . The trial consist Screening phase approximately 4 week , treatment phase 48 week depend participant ' individual virologic response , follow-up phase least 24 week . All participant receive 12 week telaprevir treatment combination standard therapy . At Week 12 , telaprevir dose end participant continue standard therapy . Participants randomly assign receive one two different dosage regimen telaprevir ( 750 milligram [ mg ] every 8 hour ( hr ) , 1125 mg every 12 hr ) combination standard therapy ( pegylated interferon [ Peg-IFN ] -alfa-2a ribavirin [ RBV ] Peg-IFN-alfa-2b RBV standard dos ) . Efficacy evaluate HCV Ribonucleic Acid ( RNA ) value , viral response , viral breakthrough , partial response , early viral kinetics sustain viral response . Pharmacokinetics , Pharmacokinetic-pharmacodynamic relationship also evaluate . Safety monitor throughout study duration .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Chronic genotype 1 Hepatitis ( inflammation liver ) C infection Never treat Hepatitis C Viral ( HCV ) infection No clinically significant lab abnormality Amount HCV Ribonucleic acid ( RNA ) blood 10,000 international units/milliliter ( IU/mL ) entry Liver biopsy `` Fibroscan '' test perform screen past 3 year Contraindications start antiHCV therapy History evidence liver cirrhosis ( serious liver disorder connective tissue replaces normal liver tissue , liver failure often occur ) decompensated liver disease Any evidence significant liver disease addition Hepatitis C Infected Human Immunodeficiency Virus ( lifethreatening infection get infect person 's blood sex infect person ) Hepatitis B Women pregnant ( carry unborn baby ) , plan pregnant breastfeeding partner woman pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Genotype 1</keyword>
	<keyword>Telaprevir</keyword>
	<keyword>Treatment-na√Øve</keyword>
	<keyword>VX-950-C208</keyword>
	<keyword>VX-950-TiDP24-C208</keyword>
</DOC>